Special Issue "Therapeutic Strategies in Cholangiocarcinoma"

A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Gastrointestinal Oncology".

Deadline for manuscript submissions: 30 November 2022 | Viewed by 696

Special Issue Editor

Dr. Nathalie S. Guedj
E-Mail Website
Guest Editor
Hôpital Beaujon, Clichy, France
Interests: colorectal pathology; intrahepatic cholangiocarcinomas

Special Issue Information

Dear Colleagues,

Cholangiocarcinomas (CCA) are heterogeneous highly malignant tumor developed from the biliary tract. It is the second most common primary liver malignancy. Its incidence in Europe and North America has significantly increased without any reason clearly identified. The prognosis is dismal mainly due to tumor aggressiveness, late diagnosis and poor response to current therapies. Three principal forms are described according to their location: intrahepatic, peri-hilar and distal CCA. Interestingly, each subtype has a distinct epidemiology, biology, prognosis, carcinogenesis and molecular alterations responsible of a specific clinical strategy management and with the importance to make an accurate diagnosis. The offer of therapeutic possibility in CCA is wide, ranging from surgery only potentially curative treatment for earlier stage of CCA to targeted therapies depending on molecular alterations. In this special issue about therapeutic strategies of CCA, we will discuss firstly, the importance of the diagnostic process from the point of view of the clinician, the pathologist and the radiologist. In a second step we will deal with the various current therapeutic possibilities. Finally, we will say a word on therapeutic perspectives.

Dr. Nathalie S. Guedj
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cholangiocarcinoma
  • therapeutic
  • diagnosis

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Review
Surgical Treatment of Distal Cholangiocarcinoma
Curr. Oncol. 2022, 29(9), 6674-6687; https://doi.org/10.3390/curroncol29090524 - 17 Sep 2022
Viewed by 487
Abstract
Distal cholangiocarcinoma (dCCA) is a rare malignancy arising from the epithelial cells of the distal biliary tract and has a poor prognosis. dCCA is often clinically silent and patients commonly present with locally advanced and/or distant disease. For patients identified with early stage, [...] Read more.
Distal cholangiocarcinoma (dCCA) is a rare malignancy arising from the epithelial cells of the distal biliary tract and has a poor prognosis. dCCA is often clinically silent and patients commonly present with locally advanced and/or distant disease. For patients identified with early stage, resectable disease, surgical resection with negative margins remains the only curative treatment strategy available. However, despite appropriate treatment and diligent surveillance, risk of recurrence remains high with nearly 50% of patients experiencing recurrence at 5 years subsequent to surgical resection; therefore, it is prudent to continue to optimize neoadjuvant and adjuvant therapies in order to reduce the risk of recurrence and improve overall survival. In this review, we discuss the clinical presentation, workup and surgical treatment of dCCA. Full article
(This article belongs to the Special Issue Therapeutic Strategies in Cholangiocarcinoma)
Back to TopTop